Navigation Links
Abt Associates Clinical Trials Announces Name Change to Abt Bio-Pharma Solutions, Inc.
Date:4/1/2008

Reflects Full Scope of Integrated Global Services

CAMBRIDGE, Mass., April 1, 2008 /PRNewswire/ -- Abt Associates Clinical Trials today launches under a new name, Abt Bio-Pharma Solutions, Inc., a wholly owned subsidiary of Abt Associates Inc. The company will continue to provide custom strategic, research and communication solutions for the pharmaceutical, biotechnology, medical device and diagnostics industries utilizing a team approach that blends decades of experience with wide ranging technical and therapeutic area expertise.

Abt Bio-Pharma Solutions (ABS) offers a wide range of integrated services across the product lifecycle, including health economics and outcomes research, registries and other real world studies, clinical trials, biometrics and marketing consulting and research. Experienced professional staff lead cross-functional teams that are better able to address the complex issues facing the bio-pharma industry. Sponsors find that this integrated, collaborative approach promotes cost- and time-effective solutions to their business problems, with the result that the organization has grown 30 percent over the past year.

"ABS helps sponsors achieve success for their products in a very competitive marketplace," said Steven Fosburg, Executive Vice President and Managing Director of ABS. "We will leverage the increased flexibility that our new organization affords to invest in staff and resources to meet the expanding needs of our global client base without sacrificing any of the scientific rigor or timeliness that we are known for." ABS will open an office in Basel, Switzerland in May 2008.

Abt Associates has been a leader in healthcare-related research since 1965. "Abt Associates has a strong commitment to improving the health of people and communities around the world," said Wendell J. Knox, President and CEO of Abt Associates. "Abt Bio-Pharma Solutions is well positioned to respond to the clinical research and marketing challenges our clients face as they bring new products and solutions to market." As a subsidiary of Abt Associates, ABS is able to call on the company's extensive research services, knowledge base and technical expertise.

Abt Associates applies scientific research, technical assistance and consulting expertise to a wide range of social, economic and health policy issues; international development; bio-pharma industry issues; and complex business problems. Founded in 1965, the company provides services to U.S. federal, state and local governments; universities and foundations; media; and major corporations. Its staff of over 1,000 is located in Cambridge, Lexington (Abt Bio-Pharma Solutions, Inc.), and Hadley, Massachusetts; Bethesda, Maryland; Durham, North Carolina; Chicago Illinois; New York, New York (SRBI), and in Africa, Asia, Central Asia, Europe, Latin America, and the Middle East.


'/>"/>
SOURCE Abt Associates
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NSF International Acquires David Begg Associates
2. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
3. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes
4. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes - Correction
5. QED International Associates Announces Changes to the HealthShares(TM) Composite, HealthShares(TM) Cancer and HealthShares(TM) Neuroscience Indexes
6. QED International Associates Announces Changes to the HealthShares(TM) Composite and HealthShares(TM) Respiratory/Pulmonary Indexes
7. Halogen Receives High Ratings from Bersin & Associates - Company recognized as a market leader, and receives praise for outstanding customer satisfaction
8. QED International Associates Announces Changes to the HealthShares(TM) Dermatology and Wound Care Index
9. Lambert, Edwards & Associates Named Agency of Record for The West Michigan Science & Technology Initiative
10. QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes (As Revised)
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 8, 2016 Eutilex Co. Ltd. today announced ... $18.9M) Series A financing. This financing round included participation ... and SNU Bio Angel. This new funding brings the ... (US $27.7M) since its founding in 2015. ... development and commercialization of its immuno-oncology programs, expand its ...
(Date:12/7/2016)... ... December 07, 2016 , ... ACEA ... dose escalation and expansion clinical trial for its lead drug candidate, AC0010, at ... of the trial was to determine the safety, antitumor activity, and recommended phase ...
(Date:12/7/2016)... LANSING, Mich. , Dec. 7, 2016 ... it has named Dr. Dan Kephart as ... the company. Kephart will assume his responsibilities at Neogen ... research and development director for the agribusiness unit of ... food safety development at Life Technologies. His extensive industry ...
(Date:12/7/2016)... 2016  Nordion, a standalone business of Sterigenics ... today,s award by the United States Department of ... the Phase II cooperative agreement funding to GA ... University of Missouri Research Reactor Center (MURR ® ... establishment of a new, reliable supply of molybdenum ...
Breaking Biology Technology:
(Date:11/22/2016)... , November 22, 2016 According to the new ... Palm Print, Face, Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), Function ... by MarketsandMarkets, the market is expected to grow from USD 10.74 Billion ... of 16.79% between 2016 and 2022. Continue ... ...
(Date:11/17/2016)... , Nov. 17, 2016 Global Market Watch: ... Biobanks (Disease-Based Banks, Population-Based Banks and Academics) market is to ... for Private Biobanks shows the highest Compounded Annual Growth Rate ... region during the analysis period 2014-2020. North ... of 9.95% followed by Europe at ...
(Date:11/15/2016)... Research and Markets has announced the addition of the "Bioinformatics ... ... The global bioinformatics market is projected ... in 2016, growing at a CAGR of 21.1% during the forecast ... by the growing demand for nucleic acid and protein sequencing, increasing ...
Breaking Biology News(10 mins):